Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: A prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis

Stroke

Volumn 44, Issue 8, 2013, Pages 2232-2239

  Hankey, Graeme J ^a,b   Ford, Andrew H ^c   Yi, Qilong ^d   Eikelboom, John W ^e   Lees, Kennedy R ^f   Chen, Christopher ^g   Xavier, Denis ^h   Navarro, Jose C ⁱ   Ranawaka, Udaya K ^j   Uddin, Wasim ^k   Ricci, Stefano ^l   Gommans, John ^m   Schmidt, Reinhold ⁿ   Almeida, Osvaldo P ^c   Van Bockxmeer, Frank M ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CANADIAN BLOOD SERVICES   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

ⁱ Jose R Reyes Memorial Medical Center   (Philippines)

^j UNIVERSITY OF KELANIYA   (Sri Lanka)

^k POF Hospital   (Pakistan)

^l UO Neurologia   (Italy)

^m HAWKE S BAY HOSPITAL   (New Zealand)

ⁿ MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

clinical trial; cognitive impairment; homocysteine; vitamin B complex

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; VITAMIN SUPPLEMENTATION;

CLINICAL TRIAL; COGNITIVE IMPAIRMENT; HOMOCYSTEINE; VITAMIN B COMPLEX;

AGED; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLACEBOS; RECURRENCE; STROKE; TREATMENT OUTCOME; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 84880820784     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001886     Document Type: Article

References (35)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117. (Pubitemid 41797645)
2. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confrmed Alzheimer disease. Arch Neurol. 1998;55:1449-1455. (Pubitemid 28525506)
3. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483. (Pubitemid 34441738)
4. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr. 2004;80:114-122. (Pubitemid 41115564)
5. Zylberstein DE, Lissner L, Björkelund C, Mehlig K, Thelle DS, Gustafson D, et al. Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol Aging. 2011;32:380-386.
6. Ford AH, Flicker L, Alfonso H, Hankey GJ, Norman PE, van Bockxmeer FM, et al. Plasma homocysteine and MTHFRC677T polymorphism as risk factors for incident dementia. J Neurol Neurosurg Psychiatr. 2012;83:70-75.
7. Ford AH, Flicker L, Hankey GJ, Norman P, van Bockxmeer FM, Almeida OP. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism and cognitive impairment: the health in men study. Mol Psychiatry. 2012;17:559-566.
8. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology. 2004;62:1972-1976. (Pubitemid 38738206)
9. Ariogul S, Cankurtaran M, Dagli N, Khalil M, Yavuz B. Vitamin B12, folate, homocysteine and dementia: are they really related? Arch Gerontol Geriatr. 2005;40:139-146. (Pubitemid 40186919)
10. Van Dam F, Van Gool WA. Hyperhomocysteinemia and Alzheimer's disease: a systematic review. Arch Gerontol Geriatr. 2009;48:425-430.
11. Seal EC, Metz J, Flicker L, Melny J. A randomized, double-blind, placebo-controlled study of oral vitamin B12 supplementation in older patients with subnormal or borderline serum vitamin B12 concentrations. J Am Geriatr Soc. 2002;50:146-151. (Pubitemid 34053035)
12. Clarke R, Harrison G, Richards S; Vital Trial Collaborative Group. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med. 2003;254:67-75. (Pubitemid 36819131)
13. Garcia A, Pulman K, Zanibbi K, Day A, Galaraneau L, Freedman M. Cobalamin reduces homocysteine in older adults on folic acid-fortifed diet: a pilot, double-blind, randomized, placebo-controlled trial. J Am Geriatr Soc. 2004;52:1410-1412. (Pubitemid 39038226)
14. Hvas AM, Juul S, Lauritzen L, Nexø E, Ellegaard J. No effect of vitamin B-12 treatment on cognitive function and depression: a randomized placebo controlled study. J Affect Disord. 2004;81:269-273. (Pubitemid 39141916)
15. Lewerin C, Matousek M, Steen G, Johansson B, Steen B, Nilsson-Ehle H. Signifcant correlations of plasma homocysteine and serum meth-ylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study. Am J Clin Nutr. 2005;81:1155-1162. (Pubitemid 41724959)
16. Stott DJ, MacIntosh G, Lowe GD, Rumley A, McMahon AD, Langhorne P, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr. 2005;82:1320-1326. (Pubitemid 43779732)
17. Eussen SJ, de Groot LC, Joosten LW, Bloo RJ, Clarke R, Ueland PM, et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 defciency: a randomized, placebo-controlled trial. Am J Clin Nutr. 2006;84:361-370. (Pubitemid 44699146)
18. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006;354:2764-2772. (Pubitemid 43974194)
19. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007;369:208-216. (Pubitemid 46107683)
20. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al; Alzheimer Disease Cooperative Study. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300:1774-1783.
21. Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cho-linesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry. 2008;23:155-160. (Pubitemid 351308495)
22. Kang JH, Cook N, Manson J, Buring JE, Albert CM, Grodstein F. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr. 2008;88:1602-1610.
23. Ford AH, Flicker L, Alfonso H, Thomas J, Clarnette R, Martins R, et al. Vitamins B(12), B(6), and folic acid for cognition in older men. Neurology. 2010;75:1540-1547.
24. Knopman DS, Roberts RO, Geda YE, Pankratz VS, Christianson TJ, Petersen RC, et al. Validation of the telephone interview for cognitive status-modifed in subjects with normal cognition, mild cognitive impairment, or dementia. Neuroepidemiology. 2010;34:34-42.
25. Wald DS, Kasturiratne A, Simmonds M. Effect of folic acid, with or without other B vitamins, on cognitive decline: meta-analysis of randomized trials. Am J Med. 2010;123:522-527.e2.
26. Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr. 2011;30:297-302.
27. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2012;27:592-600.
28. Ford AH, Almeida OP. Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials. J Alzheimers Dis. 2012;29:133-149.
29. Hankey GJ, Algra A, Chen C, Wong MC, Cheung R, Wong L, et al. VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). Int J Stroke 2007;2:144-150. (Pubitemid 46691714)
30. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol. 2010;9:855-865.
31. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
32. Srikanth V, Thrift AG, Fryer JL, Saling MM, Dewey HM, Sturm JW, et al. The validity of brief screening cognitive instruments in the diagnosis of cognitive impairment and dementia after frst-ever stroke. Int Psychogeriatr. 2006;18:295-305. (Pubitemid 43829879)
33. Godefroy O, Fickl A, Roussel M, Auribault C, Bugnicourt JM, Lamy C, et al. Is the Montreal Cognitive Assessment superior to the Mini-Mental State Examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation. Stroke. 2011;42:1712-1716.
34. Pendlebury ST, Mariz J, Bull L, Mehta Z, Rothwell PM. MoCA, ACER, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke. 2012;43:464-469.
35. Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol. 2005;4:752-759. (Pubitemid 41457291)